Download PDF
Dtsch Med Wochenschr 2018; 143(05): 357-359
DOI: 10.1055/s-0043-111861
Standpunkt
© Georg Thieme Verlag KG Stuttgart · New York

Persistierendes Foramen ovale und ischämischer Schlaganfall: Aktuelle Aspekte

Closure of Patent Foramen Ovale after Ischemic Stroke: an Update
Jakob Kluge
,
Armin Grau
Further Information

Publication History

Publication Date:
05 March 2018 (online)

Also available at
    Permissions and Reprints

Abstract

The value of interventional closure of patent foramen ovale (PFO) after cryptogenic stroke has been controversial. Recently, two randomized controlled trials showed a benefit of interventional closure of PFO compared to antiplatelet therapy only. We give a survey of the current literature and express questions that still remain unacknowledged.

Das persistierende Foramen ovale kann mit einem ischämischen Schlaganfall zusammenhängen. Sollte es also interventionell verschlossen werden? Leitlinien raten noch zur Zurückhaltung, aber aktuelle Studien zeigen, dass der Eingriff bei einigen Patienten durchaus sinnvoll sein kann. Ein Standpunkt-Artikel aus der Sicht eines Neurologen, in dem auch die noch offenen Fragen betont werden.

Schlüsselwörter

Persistierendes Foramen ovale (PFO) - PFO-Verschluss - ischämischer Schlaganfall - kryptogener Schlaganfall

Key words

patent foramen ovale (PFO) - closure of PFO - ischemic stroke - cryptogenic stroke
 

  • Literatur

  • 1 Mas JL, Derumeaux G, Guillon B. et al. Patent Foramen Ovale Closure or Anticoagulation vs. Platelets after Stroke. N Engl J Med 2017; 377: 1011-1021
    CrossrefPubMedGoogle Scholar
  • 2 Søndergaard L, Kasner SE, Rhodes JF. et al. Patent Foramen Ovale Closure or Antiplatelet Therapy for Cryptogenic Stroke. N Engl J Med 2017; 377: 1033-1042
    CrossrefPubMedGoogle Scholar
  • 3 Saver JL, Carroll JD, Thaler DE. et al. Long-Term Outcomes of Patent Foramen Ovale Closure or Medical Therapy after Stroke. N Engl J Med 2017; 377: 1022-1032
    CrossrefPubMedGoogle Scholar
  • 4 Hagen PT, Scholz DG, Edwards WD. Incidence and size of patent foramen ovale during the first 10 decades of life: an autopsy study of 965 normal hearts. Mayo Clin Proc 1984; 59: 17-20
    CrossrefPubMedGoogle Scholar
  • 5 Lechat P, Mas JL, Lascault G. et al. Prevalence of patent foramen ovale in patients with stroke. N Engl J Med 1988; 318: 1148-1152
    CrossrefPubMedGoogle Scholar
  • 6 Farb A, Ibrahim NG, Zuckerman BD. Patent Foramen Ovale after Cryptogenic Stroke – Assessing the Evidence for Closure. N Engl J Med 2017; 377: 1006-1009
    CrossrefPubMedGoogle Scholar
  • 7 Sun YP, Homma S. Patent Foramen Ovale and Stroke. Circ J 2016; 80: 1665-1673
    CrossrefPubMedGoogle Scholar
  • 8 Kent DM, Ruthazer R, Weimar C. et al. An index to identify stroke-related vs incidental patent foramen ovale in cryptogenic stroke. Neurology 2013; 81: 619-625
    CrossrefPubMedGoogle Scholar
  • 9 Furlan AJ, Reisman M, Massaro J. et al. Closure or Medical Therapy for Cryptogenic Stroke with Patent Foramen Ovale. N Engl J Med 2012; 366: 991-999
    CrossrefPubMedGoogle Scholar
  • 10 Meier B, Kalesan B, Mattle HP. et al. Percutaneous Closure of Patent Foramen Ovale in Cryptogenic Embolism. N Engl J Med 2013; 368: 1083-1091
    CrossrefPubMedGoogle Scholar
  • 11 Carroll JD, Saver JL, Thaler DE. et al. Closure of Patent Foramen Ovale versus Medical Therapy after Cryptogenic Stroke. N Engl J Med 2013; 368: 1092-1100
    CrossrefPubMedGoogle Scholar
  • 12 Messé SR, Gronseth G, Kent DM. et al. Practice advisory: Recurrent stroke with patent foramen ovale (update of practice parameter). Neurology 2016; 87: 815-821
    CrossrefPubMedGoogle Scholar
  • 13 Kernan WN, Ovbiagele B, Black HR. et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2014; 45: 2160-2236
    CrossrefPubMedGoogle Scholar
  • 14 Deutsche Gesellschaft für Neurologie, Deutsche Schlaganfallgesellschaft. Primär- und Sekundärprävention der zerebralen Ischämie: Gemeinsame Leitlinie der Deutschen Gesellschaft für Neurologie (DGN) und der Deutschen Schlaganfallgesellschaft (DSG). 2008
    PubMedGoogle Scholar
  • 15 Homma S, Sacco RL, Di Tullio MR. et al. Effect of medical treatment in stroke patients with patent foramen ovale: patent foramen ovale in Cryptogenic Stroke Study. Circulation 2002; 105: 2625-2631
    CrossrefPubMedGoogle Scholar
  • 16 Shariat A, Yaghoubi E, Farazdaghi M. et al. A comparison of medical treatments in cryptogenic stroke patients with patent foramen ovale: a randomized clinical trial. J Res Med Sci 2013; 18: 94-98
    PubMedGoogle Scholar
  • 17 Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS). Im Internet: clinicaltrials.gov https://clinicaltrials.gov/ct2/show/NCT02239120?cond=Respect+Esus&rank=1 ; Stand: 18.01.2018
    PubMedGoogle Scholar
  • 18 Apixaban for Treatment of Embolic Stroke of Undetermined Source. Im Internet: clinicaltrials.gov https://clinicaltrials.gov/ct2/show/NCT02427126?cond=Apixaban+for+Treatment+of+Embolic+Stroke+of+Undetermined&rank=1 ; Stand: 18.01.2018
    PubMedGoogle Scholar
  • 19 Staubach S, Steinberg DH, Zimmermann W. et al. New onset atrial fibrillation after patent foramen ovale closure. Catheter Cardiovasc Interv 2009; 74: 889-895
    CrossrefPubMedGoogle Scholar